Early-phase clinical trials reported disease control of 59.3% for invikafusp, a novel dual T-cell agonist, in advanced solid tumors. The report emphasized tolerability alongside the mid-stage activity metric, supporting further development. For investors and developers, a disease-control rate in this range can help guide dose-escalation and expansion cohort design as teams refine combination strategies and stratification markers.